MyBioSource

antibody

Goat anti Apolipoprotein CIII

MBS315849

1 mg

465 USD

polyclonal

goat

human

enzyme immunoassay, ELISA, western blot

MBS315849

Antibody

Goat anti Apolipoprotein CIII

Apolipoprotein CIII (Apo CIII)

Goat Antibody to Human Apolipoprotein CIII (Apo CIII)

apolipoprotein C-III; Apolipoprotein C-III; apolipoprotein C-III; apo-CIII; apoC-III; apolipoprotein C3; OTTHUMP00000043270; OTTHUMP00000069353; apolipoprotein C-III; Apolipoprotein C3

APOC3; APOC3; APOCIII; MGC150353; N/A

APOC3_HUMAN

Polyclonal

Goat

99

Apolipoprotein CIII (Apo CIII). Binds to human Apo CIII.

Human Apo CIII-Sepharose affinity column

Affinity Purified, Liquid

1mg/ml (OD280nm, E^0.1% = 1.35)

Short-term store at 2 to 8 degree C. Long term store at -20 degree C. Avoid multiple/freeze thaw cycles.

EIA/ELISA, Western Blot

Can be used for detection of Apo CIII in plasma and lipoproteins, for immunoassay, immunoblotting, enzyme conjugation, or biotinylation. Dilution for immunoblot ELISA: 1:5,000 to 1:40,000. Each laboratory should determine an optimum working titer for use

Immunogen: Purified human Apolipoprotein CIII

Buffer: 75mM PBS, pH 7.2 containing 0.5mM EDTA. Preservative: 0.02% Sodium azide. Important Note: Centrifuge before opening to ensure complete recovery of vial contents. Warnings: This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1 - 1.0 %. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.

Polyclonal Antibodies to Lipoproteins

Harwood, H.J., et al., (2003), "Isozyme-nonselective N-Substituted Bipiperidylcarboxamide Acetyl-CoA Carboxylase Inhibitors Reduce Tissue Malonyl-CoA Concentrations, Inhibit Fatty Acid Synthesis, and Increase Fatty Acid Oxidation in Cultured C

4557323

NP_000031.1

NM_000040.1

P02656

10,852 Da

Chylomicron-mediated Lipid Transport Pathway 106157!!HDL-mediated Lipid Transport Pathway 106158!!Lipid Digestion, Mobilization, And Transport Pathway 106111!!Lipoprotein Metabolism Pathway 106156!!Metabolism Of Lipids And Lipoproteins Pathway 160976!!PPAR Signaling Pathway 83042!!PPAR Signaling Pathway 450!!Statin Pathway 198852

Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia. [provided by RefSeq]

Function: Inhibits lipoprotein lipase and hepatic lipase and decreases the uptake of lymph chylomicrons by hepatic cells. This suggests that it delays the catabolism of triglyceride-rich particles. Subcellular location: Secreted. Tissue specificity: Constitutes 50% of the protein fraction of VLDL and 2% of that of HDL. Synthesized predominantly in liver and to a lesser degree in intestine. Post-translational modification: O-linked glycan consists of Gal-GalNAc disaccharide, further modified with up to 3 sialic acid residues. O-glycosylated on Thr-94 with a core 1 or possibly core 8 glycan. Ref.9 Ref.10. Involvement in disease: Defects in APOC3 may be a cause of hyperalphalipoproteinemia (HYPALIP) [. MIM:143470]. Affected individuals show high levels of alpha-lipoprotein (high density lipoprotein/HDL). Ref.11. Sequence similarities: Belongs to the apolipoprotein C3 family.

1 mg

465 USD